H.C. Wainwright lowered the firm’s price target on Kyverna Therapeutics (KYTX) to $6 from $7 and keeps a Neutral rating on the shares following the Q3 report. The target drop reflects operating expense adjustments and change in potentially dilutive shares outstanding, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics price target lowered to $24 from $44 at Wells Fargo
- Kyverna Therapeutics Reports Q3 Loss Amid Rising R&D Costs
- Kyverna Therapeutics anounces patient data on KYV-101
- Kyverna Therapeutics Advances in Cell Therapy Leadership
- Kyverna Therapeutics reports Q3 EPS (80c), consensus (79c)